Loading candles…
Neuland Laboratories Limited operates in the pharmaceutical and chemical industries, specializing in the development and manufacture of Active Pharmaceutical Ingredients (APIs) as well as providing Contract Development and Manufacturing Organization (CDMO) services. The company serves both domestic and international markets, distributing products in over 80 countries. Its business segments include Generic APIs (GDS) and Custom Manufacturing Solutions (CMS). Neuland Laboratories offers end-to-end solutions that span from pre-investigational new drug (pre-IND) stages through commercial supply. The company emphasizes adherence to high-quality standards and regulatory compliance across a range of therapeutic areas. No information is provided regarding the company's year of incorporation, founders, key management, subsidiaries, or stock exchange listings.
This page is a live market overview for NEULAND LAB LTD. (NEULANDLAB) on the NSE. As a listed security, NEULAND LAB LTD. is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for NEULANDLAB before placing trades on tick2trade.
As of the latest feed, NEULANDLAB last traded at ₹22,855 on NSE, up ₹1,312 (6.09%) from the previous close of ₹21,543. Today's session range is ₹21,601 – ₹23,500, against a 52-week band of ₹11,500 – ₹23,500. Traded volume today stands at 3.14L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for NEULANDLAB in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether NEULANDLAB is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for NEULAND LAB LTD. before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in NEULANDLAB. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated NEULANDLAB option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 5 Aug 2026 |
| Audited Results - Q4 & FY26 | Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial… | 12 May 2026 |
| Unaudited Results - Q3-FY25 | Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2025 | 9 Feb 2026 |
| Results - Q2 & FY25 | To consider and approve the financial results for the quarter and half year ended September 30, 2025 | 7 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 31 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 15 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.